MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...
Investor's Business Daily on MSN18h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback